Esophageal Squamous Cell Carcinoma Clinical Trials

77 recruiting

Esophageal Squamous Cell Carcinoma Trials at a Glance

123 actively recruiting trials for esophageal squamous cell carcinoma are listed on ClinicalTrialsFinder across 6 cities in 31 countries. The largest study group is Phase 2 with 71 trials, with the heaviest enrollment activity in Shanghai, Shanghai, and Fairfax. Lead sponsors running esophageal squamous cell carcinoma studies include Fudan University, Anhui Provincial Hospital, and Shanghai Zhongshan Hospital.

Browse esophageal squamous cell carcinoma trials by phase

Treatments under study

About Esophageal Squamous Cell Carcinoma Clinical Trials

Looking for clinical trials for Esophageal Squamous Cell Carcinoma? There are currently 77 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Esophageal Squamous Cell Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Esophageal Squamous Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 123 trials

Recruiting
Phase 1Phase 2

A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

Oesophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC60 enrolled7 locationsNCT07405151
Recruiting
Phase 2

Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)
Second Affiliated Hospital of Zunyi Medical University92 enrolled1 locationNCT07559045
Recruiting
Phase 2

Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)
University Hospital, Clermont-Ferrand95 enrolled30 locationsNCT07205731
Recruiting
Phase 3

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)
Qilu Pharmaceutical Co., Ltd.466 enrolled1 locationNCT07463573
Recruiting
Phase 2

A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Advanced Esophageal Squamous Cell Carcinoma
Shanghai Junshi Bioscience Co., Ltd.280 enrolled1 locationNCT07484724
Recruiting
Phase 1

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

Head and Neck CancerHNSCCColo-rectal Cancer+4 more
ALX Oncology Inc.170 enrolled7 locationsNCT07085091
Recruiting
Phase 1

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled158 locationsNCT04389632
Recruiting

Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC

Locally Advanced Esophageal Squamous Cell Carcinoma
Shandong Provincial Hospital30 enrolled1 locationNCT07549100
Recruiting
Phase 2

Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Nanfang Hospital, Southern Medical University30 enrolled1 locationNCT06885814
Recruiting
Phase 1Phase 2

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

Squamous Cell CarcinomaAdvanced or Metastatic Squamous Non-Small Cell Lung CancerAdvanced Head and Neck Squamous Cell Carcinoma+4 more
Hummingbird Bioscience398 enrolled20 locationsNCT05910827
Recruiting
Phase 2

Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC

Esophageal Squamous Cell CarcinomaLocally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Sichuan University118 enrolled1 locationNCT07519486
Recruiting
Phase 1

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

Esophageal Squamous Cell CarcinomaCutaneous Squamous Cell CancerBladder Cancer+8 more
EvolveImmune United, Inc160 enrolled9 locationsNCT07217171
Recruiting
Phase 2

Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC

Esophageal Squamous Cell Carcinoma
Fudan University104 enrolled1 locationNCT07403136
Recruiting
Phase 2

Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Ning Jiang, M.D./Ph.D.98 enrolled1 locationNCT07530094
Recruiting
Phase 1

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Metastatic Solid TumorEsophageal Squamous Cell CarcinomaGastric Adenocarcinoma+2 more
Plexium, Inc.155 enrolled10 locationsNCT07284186
Recruiting
Phase 3

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8+10 more
NRG Oncology300 enrolled95 locationsNCT03801876
Recruiting
Phase 1Phase 2

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC298 enrolled42 locationsNCT06780111
Recruiting
Phase 1

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Esophageal Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaHigh Grade Serous Ovarian Cancer
IDEAYA Biosciences150 enrolled5 locationsNCT07503808
Recruiting
Phase 1

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Ovarian CancerCervical Cancer+4 more
Radiopharm Theranostics, Ltd9 enrolled2 locationsNCT05799274
Recruiting
Phase 2

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)+2 more
AstraZeneca257 enrolled59 locationsNCT06535607